Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

Inclusion Criteria:

• Histologic confirmation of breast malignancy with TNM staging.

• Patients must have undergone a mastectomy with or without reconstruction within the past 120 days if not receiving adjuvant therapy, or within 60 days after completion of the last dose of chemotherapy.

• No prior radiotherapy to any portion of the planned treatment site.

• No documented history of adhesive or tape allergy.

• Patients must be scheduled to receive conventionally fractionated photon-based radiation. Patients planning brachytherapy within the treatment field, and patients scheduled to receive bilateral radiation or hypofractionated radiation are not eligible.

• No active rash or pre-existing dermatitis within the treatment field.

• No co-existing medical conditions resulting in life expectancy < 2 years.

• No active collagen vascular diseases (i.e. lupus erythematosus, scleroderma, dermatomyositis).

• No concomitant cytotoxic chemotherapy. Endocrine therapy and HER2 directed therapies are allowed.

• No current inflammatory breast cancer, or gross dermal involvement at initiation of radiotherapy.

• No previous history of organ or bone marrow transplant.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

• In order to complete the mandatory patient-completed measures, participants must be able to speak and read English.